Qiagen
Company Snapshot
Company Overview
Qiagen NV, a leading diagnostics company, specializes in DNA, RNA and protein technologies. The company offers tissue- and liquid biopsy-based assays for personalized healthcare, focusing on companion diagnostics for cancer treatment. Qiagen operates in more than 35 countries, serving 500,000 customers. The NGS clinical market, infectious disease diagnostics and prenatal testing are vital areas. The company provides solutions for genetic information and identifying abnormalities in developing fetuses. Qiagen’s NGS products focus on sample preparation, including REPLI-g kits and QIAxpert for nucleic acid evaluation. The company also markets kits for extracting circulating cfDNA from blood samples and liquid biopsy tests for prostate and lung cancers licensed from Johns Hopkins University.
Financial Highlights (FY 2023)
This information is available for BCC Research members only.
Company's Business Segments
- Molecular diagnostics : Molecular testing, Oncology, Infectous diseases and Immune Monitoring
- Life Sciences : Medicine and clinical development, frorensics, exploring the building blocks of life.
Applications/End User Industries
- Real-Time PCR Instrumentation
- Nucleic Acid Amplification
- Automated Systems
- Automated Sample Preparation
- High-Throughput Testing
- Point-of-Care Diagnostic Systems
- Rapid Testing
- Clinical Settings
- Next-Generation Sequencing (NGS)
- Automated Liquid Handling
- Oncology
- Infectious Diseases
- Molecular Pathology
- Tissue Extraction Kits
- Tissue-Based Diagnostics
- Life Sciences Research
- Genomics
- Transcriptomics
- Proteomics
- High-Throughput DNA Sequencing
